Showing results (931-940 of 973) with videos related to

Sort By:
Pageof 98
Bioorganic & Medicinal Chemistry|December 1, 2010
ApoA-I mimetic peptides promote pre-β HDL formation in vivo causing remodeling of HDL and triglyceride accumulation at higher doseEster Carballo-Jane, Zhu Chen, Edward O'Neill, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 2, 2010
Antiobesity effect of MK-5046, a novel bombesin receptor subtype-3 agonistXiao-Ming Guan, Joseph M Metzger, Liming Yang, et al.
Nature Genetics|September 6, 2000
Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body massA S Chen, D J Marsh, M E Trumbauer, et al.
British Journal of Pharmacology|September 25, 2009
Down-regulation of the Notch pathway mediated by a gamma-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemiaJ Tammam, C Ware, C Efferson, et al.
Journal of Lipid Research|October 30, 2012
Nicotinic acid and DP1 blockade: studies in mouse models of atherosclerosisAlison M Strack, Ester Carballo-Jane, Sheng-Ping Wang, et al.
Journal of Lipid Research|March 19, 2011
The use of stable-isotopically labeled oleic acid to interrogate lipid assembly in vivo: assessing pharmacological effects in preclinical speciesDavid G McLaren, Timothy He, Sheng-Ping Wang, et al.
Bioorganic & Medicinal Chemistry Letters|February 3, 2007
Lead optimization of 5,6-diarylpyridines as CB1 receptor inverse agonistsChristina B Madsen-Duggan, John S Debenham, Thomas F Walsh, et al.
Bioorganic & Medicinal Chemistry Letters|November 3, 2005
Synthesis of functionalized 1,8-naphthyridinones and their evaluation as novel, orally active CB1 receptor inverse agonistsJohn S Debenham, Christina B Madsen-Duggan, Thomas F Walsh, et al.
Cancer Immunology, Immunotherapy : CII|February 17, 2019
A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancerMartin Sebastian, Andreas Schröder, Birgit Scheel, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of MK-7725, A Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of ObesityHarry R Chobanian, Yan Guo, Ping Liu, et al.
Pageof 98